Effectiveness and Cost-Effectiveness of Non-Pharmacological Interventions among Chinese Adults with Prediabetes: A Protocol for Network Meta-Analysis and CHIME-Modeled Cost-Effectiveness Analysis

被引:1
|
作者
Yin, Yue [1 ,2 ]
Tu, Yusi [1 ,2 ]
Zhao, Mingye [1 ,2 ]
Tang, Wenxi [1 ,2 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Dept Pharmacoecon, Nanjing 211198, Peoples R China
[2] China Pharmaceut Univ, Ctr Pharmacoecon & Outcomes Res, Nanjing 211198, Peoples R China
基金
中国国家自然科学基金;
关键词
prediabetes; non-pharmacological interventions; Chinese Hong Kong Integrated Modeling and Evaluation; cost-effectiveness; China; IMPAIRED GLUCOSE-TOLERANCE; DIABETES-MELLITUS; TYPE-2; PREVENTION; EXERCISE; PEOPLE;
D O I
10.3390/ijerph19031622
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Patients with prediabetes who are at a high risk of progressing to diabetes are recommended early-stage intervention, according to guidelines. Non-pharmacological interventions are effective and cost-effective for glycemic control compared with medicines. We aim to explore which non-pharmacological interventions have the greatest potential effectiveness, cost-effectiveness, and feasibility in community-based diabetes management in China. We will perform a systematic review and network meta-analysis to compare the effectiveness of included non-pharmacological interventions, then use Chinese Hong Kong Integrated Modeling and Evaluation (CHIME) to model the yearly incidence of complications, costs, and health utility for the lifetime. Published studies (only randomized controlled trials (RCTs) and cluster RCTs with at least one study arm of any non-pharmacological intervention) will be retrieved and screened using several databases. Primary outcomes included blood glucose, glycated hemoglobin, incidence of type 2 diabetes mellitus, and achievement of normoglycemia. Health utilities and cost parameters are to be calculated using a societal perspective and integrated into the modified CHIME model to achieve quality-adjusted life-year (QALY) estimates and lifetime costs. QALYs and incremental cost-effectiveness ratio will then be used to determine effectiveness and cost-effectiveness, respectively. Our study findings can inform improved diabetes management in countries with no intervention programs for these patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] What is a cost-effectiveness analysis?
    Harper, DM
    [J]. ARCHIVES OF FAMILY MEDICINE, 1997, 6 (06) : 527 - 528
  • [42] Individualized Cost-Effectiveness Analysis
    Ioannidis, John P. A.
    Garber, Alan M.
    [J]. PLOS MEDICINE, 2011, 8 (07)
  • [43] Cost-effectiveness analysis in pathology
    Raab, SS
    [J]. CLINICS IN LABORATORY MEDICINE, 1999, 19 (04) : 757 - +
  • [44] Cost-effectiveness analysis in radiology
    vanKaick, G
    Reiser, M
    [J]. RADIOLOGE, 1996, 36 (04): : 269 - 269
  • [45] Cost-effectiveness analysis in oncology
    Earle, CC
    Coyle, D
    Evans, WK
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (05) : 475 - 482
  • [46] Is cost-effectiveness analysis unfair?
    Russell, LB
    [J]. MEDICAL DECISION MAKING, 2004, 24 (02) : 232 - 234
  • [47] Cost-effectiveness analysis in surgery
    Finlayson, SRG
    Birkmeyer, JD
    [J]. SURGERY, 1998, 123 (02) : 151 - 156
  • [48] COST-EFFECTIVENESS ANALYSIS - IS IT ETHICAL
    WILLIAMS, A
    [J]. JOURNAL OF MEDICAL ETHICS, 1992, 18 (01) : 7 - 11
  • [49] COST-EFFECTIVENESS ANALYSIS FOR SURGEONS
    Koerkamp, Bas Groot
    Wang, Y. Claire
    Hunink, Myriam G. M.
    [J]. SURGERY, 2009, 145 (06) : 616 - 622
  • [50] Visualizing cost-effectiveness analysis
    Mark, DH
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (18): : 2428 - 2429